Pax Neuroscience is at the forefront of developing innovative diagnostic and therapeutic solutions for depression through its proprietary MoodMark® technology. This technology is based on proteomic biomarkers that provide a quantifiable measure of neurotransmitter activity linked to depression. By focusing on the cellular biology of depression, Pax aims to enhance the accuracy of diagnosis and the effectiveness of treatment, addressing a significant gap in psychiatric care. The company's research highlights the activation of Gsα proteins, which initiates a chemical cascade that can be measured to assess patient response to antidepressant medications, offering a faster and more objective means of evaluating treatment efficacy.

The company recognizes the challenges faced in traditional antidepressant clinical trials, including high costs and unreliable patient stratification methods. By leveraging its MoodMark® technology, Pax Neuroscience seeks to improve the predictability of drug responses and reduce the financial burden associated with drug development. The involvement of a distinguished Scientific Advisory Board, comprising leading experts in neuroscience and mental health, underscores Pax's commitment to advancing research and developing more effective treatments for depression. This innovative approach not only aims to transform patient outcomes but also to expedite the development of new therapeutic options in a field that has seen limited progress in recent years.

United States

The WHO estimates that by 2020, depression will be the leading cause of disability worldwide. Pax Neuroscience, Inc. is a clinical diagnostics company focused on development and commercialization of blood tests for depression diagnosis and for antidepressant response. These tests are based on novel protein biomarkers derived from hypothesis-driven data sets and early clinical results are promising.

Pax Neuroscience

Company Details